000			02684na a2200241 4500
003			H12O
005			20180417112753.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aPeña Mayor, Pilar de la _91765 _eNeurología
100			_aSaiz Díaz, Rosa Ana _91764 _eNeurología
245	0	0	_aEfficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: A multicentric observational study _h[artículo]
260			_bSeizure-European Journal of Epilepsy, _c2011
300			_a20(1):60-64.
500			_aFormato Vancouver: Aiguabella M, Falip M, Villanueva V, De la Peña P, Molins A, Garcia-Morales I, et al. Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a multicentric observational study. Seizure. 2011;20(1):60-4.
501			_aPMID: 21145758
504			_aContiene 22 referencias
520			_aTreatment of status epilepticus (SE) has not changed in the last few decades, benzodiazepines plus phenytoin being the most common first line treatment. Intravenous levetiracetam (ivLEV) is a new antiepileptic drug with interesting properties for SE. Material and methods: Efficacy and effectiveness of ivLEV in SE were assessed in an observational, multicentric and retrospective study. Efficacy was defined as cessation of seizures in the 24 h subsequent to starting ivLEV, with no need of any further antiepileptic drug. All patients were treated following the standard protocol (benzodiazepines plus phenytoin or valproate). ivLEV was used as add-on therapy, except in those cases with contraindication for the standard protocol, when it was administered earlier. Results: 40 patients were included, 57% men, with a mean age of 63 years. The most common type of SE was partial convulsive (90%). ivLEV was effective in approximately half of the patients (57.5%), in a mean time of 14.4 h. ivLEV was used as add-on treatment in 26 patients (after benzodiazepines plus phenytoin, valproate or both) with an efficacy of 46.1%, and as early treatment (pretreatment with benzodiazepines or nothing) in 14 patients with an efficacy of 78.5% (p 0.048). Adverse events were observed in 15% of patients. Conclusions: ivLEV was an effective antiepileptic drug for SE, but its efficacy depends on the timing of its administration, being more effective when used as early treatment, and less effective as add-on treatment. (C) 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
710			_9267 _aServicio de Neurología-Neurofisiología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/8/pc8787.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c8787 _d8787